Eton Pharmaceuticals (ETON)Oberweis Asset Management Inc added to its stake +8,000 shares

439K

Shares reported · +8,000 vs prior quarter

0.32%

Disclosed portfolio weight

$10.8M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 19, 2026Company filing · Form 8-K · ResultsReported its results
2. Apr 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
3. Apr 16, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On April 16, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the appointment of Judith Matthews as Executive Vice President, Accounting and Finance.”
4. May 14, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. May 18, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement“As disclosed in Item 1.01, on May 18, 2026, the Company entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) oral capsules with Supplier.”
2. Jul 31, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 31, 2026, Eton Pharmaceuticals, Inc. (the “Company”) appointed Danka Radosavljevic (age 42) as Chief Operating Officer. Ms. Radosavljevic previously held the position of Executive Vice President, Operations at the Company overseeing quality, product development, regulatory, supply chain and information systems for more than the past five years.”
3. Jul 31, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement“As disclosed in Item 1.01, on July 31, 2026, the Company entered into a license agreement for a late-stage rare disease product candidate, ASN-001 (timolol topical gel), from Auson for the treatment of proliferating superficial infantile hemangiomas.”
4. Aug 13, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Eton Pharmaceuticals

For Eton Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ETON page.

How this filing works

• SEC Form 13F

Other disclosures at Eton Pharmaceuticals

• SEC Form 4Oct 7, 2026
• SEC Form 144Oct 6, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRNov 14, 2025

Everything OQRO holds on this company is on its ETON page.